Mineralys Therapeutics, Inc. Common Stock

NASDAQ MLYS
$34.80 1.68 5.07%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
844.24M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
679.23M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
53.16M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
182.70 %

Upcoming events Mineralys Therapeutics, Inc. Common Stock

All events
No upcoming events scheduled

Stock chart Mineralys Therapeutics, Inc. Common Stock

Stock analysis Mineralys Therapeutics, Inc. Common Stock

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-4.48 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
3.12 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-3.87 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.94 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-55.19 -50.00

Price change Mineralys Therapeutics, Inc. Common Stock per year

8.76$ 34.80$
Min Max

Summary analysis Mineralys Therapeutics, Inc. Common Stock

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Mineralys Therapeutics, Inc. Common Stock

Revenue and net income Mineralys Therapeutics, Inc. Common Stock

All parameters

About company Mineralys Therapeutics, Inc. Common Stock

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Address:
150 N. Radnor Chester Rd., Radnor, PA, United States, 19087
Company name: Mineralys Therapeutics, Inc. Common Stock
Issuer ticker: MLYS
ISIN: US6031701013
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2023-02-10
Sector: Healthcare
Industry: Biotechnology
Site: https://mineralystx.com